News
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results